Viridian Therapeutics Inc
NASDAQ:VRDN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
11.6
25.71
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VRDN stock under the Base Case scenario is 11.01 USD. Compared to the current market price of 22.43 USD, Viridian Therapeutics Inc is Overvalued by 51%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Viridian Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VRDN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Viridian Therapeutics Inc
Balance Sheet Decomposition
Viridian Therapeutics Inc
Current Assets | 581.7m |
Cash & Short-Term Investments | 571.4m |
Other Current Assets | 10.3m |
Non-Current Assets | 4m |
PP&E | 3.3m |
Other Non-Current Assets | 659k |
Current Liabilities | 36.8m |
Accounts Payable | 3.1m |
Accrued Liabilities | 30.4m |
Other Current Liabilities | 3.3m |
Non-Current Liabilities | 19.6m |
Long-Term Debt | 17.5m |
Other Non-Current Liabilities | 2.1m |
Earnings Waterfall
Viridian Therapeutics Inc
Revenue
|
286k
USD
|
Operating Expenses
|
-251.1m
USD
|
Operating Income
|
-250.8m
USD
|
Other Expenses
|
22.7m
USD
|
Net Income
|
-228.1m
USD
|
Free Cash Flow Analysis
Viridian Therapeutics Inc
USD | |
Free Cash Flow | USD |
Viridian Therapeutics has made significant progress in 2024, completing enrollment for its THRIVE Phase III trial with 113 patients, ahead of the target of 90. THRIVE aims to evaluate the drug 001 for active thyroid eye disease (TED) with top results expected by September 2024. The company maintains a strong financial position with $613 million in cash, securing its operational runway till the second half of 2026. Additionally, the subcutaneous drug 003 looks promising, with pivotal trials set to begin mid-year. Viridian’s strategy focuses on engineering advanced therapeutics to address unmet medical needs efficiently.
What is Earnings Call?
VRDN Profitability Score
Profitability Due Diligence
Viridian Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Viridian Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
VRDN Solvency Score
Solvency Due Diligence
Viridian Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Viridian Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VRDN Price Targets Summary
Viridian Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for VRDN is 40.35 USD with a low forecast of 22.22 USD and a high forecast of 64.05 USD.
Dividends
Current shareholder yield for VRDN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VRDN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2014-06-18. The firm is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. The company has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.
Contact
IPO
Employees
Officers
The intrinsic value of one VRDN stock under the Base Case scenario is 11.01 USD.
Compared to the current market price of 22.43 USD, Viridian Therapeutics Inc is Overvalued by 51%.